



**Amendments to the Claims:**

1-159. (Cancelled)


160. (Proposed Amendment) A pharmaceutical composition, comprising a carrier and an amount of an active agent effective for treatment of bronchoconstriction, lung inflammation, lung allergy, or asthma selected from dehydroepiandrosterone, or pharmaceutically or veterinarily acceptable salts thereof, the dehydroepiandrosterone having the chemical formula




wherein the broken line represents a single or double bond; R is hydrogen or halogen; the H at position 5 is present in the alpha or beta configuration or the compound of chemical formula I comprises a racemic mixture of both configurations; and R<sub>1</sub> is ~~hydrogen or SO<sub>2</sub>OM~~, wherein M is H, Na sulfite ~~SO<sub>2</sub>O-CH<sub>2</sub>CHCH<sub>2</sub>OCOR<sub>3</sub>~~;



or phosphatide



~~wherein R<sub>2</sub> or R<sub>3</sub>, which are the same or different, is straight or branched (C1-C14) alkyl, or glucuronide~~



wherein the pharmaceutical composition comprises particles of about 1.0  $\mu\text{m}$  to about 5  $\mu\text{m}$  in size.

161. (Previously Presented) The pharmaceutical composition of claim 160, wherein said active agent is dehydroepiandrosteronesulfate.

162. (Previously Presented) The pharmaceutical composition of claim 160, which is an inhalable or nasal formulation.


163. (Cancelled)

164. (Cancelled)


165. (Previously Presented) The pharmaceutical composition of claim 160, further comprising an amount of ubiquinone (CoQn, wherein n=1 to 12) effective to reduce adenosine depletion.

166 - 186. (Cancelled)


187. (Proposed Amendment) A pharmaceutical composition, comprising a carrier and an amount of an active agent effective for treatment of bronchoconstriction, lung inflammation, lung allergy, or asthma selected from dehydroepiandrosterone, or pharmaceutically or veterinarily acceptable salts thereof, the dehydroepiandrosterone having the chemical formula




wherein the broken line represents a single or double bond; R is hydrogen or halogen; the H at position 5 is present in the alpha or beta configuration or the compound of chemical formula I comprises a racemic mixture of both configurations; and R<sub>1</sub> is ~~hydrogen or~~ SO<sub>2</sub>OM, wherein M is H, Na sulfite ~~SO<sub>2</sub>O-CH<sub>2</sub>CHCH<sub>2</sub>OCOR<sub>3</sub>~~;



or phosphatide



wherein R<sub>2</sub> or R<sub>3</sub>, which are the same or different, is straight or branched (C1-C14) alkyl, or glucuronide



wherein the pharmaceutical composition comprises particles about ~~10~~ 15  $\mu\text{m}$  to about 500  $\mu\text{m}$  in size.

188. (Previously Presented) The pharmaceutical composition of claim 187, wherein said active agent is dehydroepiandrosteronesulfate.

189. (Previously Presented) The pharmaceutical composition of claim 187, which is an inhalable or nasal formulation.

190. (Previously Presented) The pharmaceutical composition of claim 187, further comprising an amount of ubiquinone (CoQ<sub>n</sub>, wherein n=1 to 12) effective to reduce adenosine depletion in an animal tissue.